The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

More information: Robert Wood et al, Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi ...

Robert A. Wood, MD, FAAAAI, looks back on the first year of omalizumab’s use for food allergy. Patients often are allergic to multiple foods or to foods that are difficult to avoid. Perspective ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...

87.3% of white patients and 92.8% of Black patients had no severe exacerbations with omalizumab. 4% of white patients and 2.9% of Black patients had a serious adverse event with omalizumab.

3 Biologics: Targeted Solutions for Food Allergy Biologic agents, such as omalizumab, represent a promising avenue for addressing food allergies by targeting the immunologic pathways involved in ...

Director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, Robert Wood, MD led a clinical trial on omalizumab — an already FDA-approved drug ...

Robert Wood, the director of the Eudowood Division of Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, led a clinical trial on omalizumab—an already FDA-approved drug ...